NAUT
Nautilus Biotechnology Inc.
$0.68
-$0.01(-1.02%)
37
Overall
60
Value
30
Tech
21
Quality
Market Cap
$113.20M
Volume
153.40K
52W Range
$0.66 - $3.09
Target Price
$2.50
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Mar | 2022 Dec | 2023 Mar | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | -- | $589.5M | -- | $286.8M | -- | -- | ||
| Total Revenue | -- | $589.5M | -- | $286.8M | -- | -- | ||
| COST OF GOODS SOLD | ||||||||
| Cost of Revenue | -- | $441.1M | -- | $234.8M | -- | -- | ||
| GROSS PROFIT | ||||||||
| Gross Profit | -- | $148.5M | -- | $52.0M | -- | -- | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $50.5M | $173.8M | $63.6M | $145.3M | $76.2M | $81.5M | ||
| Research & Development | $29.4M | $22.8M | $37.7M | $21.8M | $47.3M | $50.5M | ||
| Research Expense | $29.4M | $22.8M | $37.7M | $21.8M | $47.3M | $50.5M | ||
| Selling, General & Administrative | $21.1M | $151.0M | $25.9M | $94.0M | $28.9M | $31.0M | ||
| Selling & Marketing Expenses | -- | $99.2M | -- | $51.5M | -- | -- | ||
| General & Administrative Expenses | $21.1M | $51.8M | $25.9M | $42.5M | $28.9M | $31.0M | ||
| Salaries & Wages | -- | $6.3M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.0M | $8.6M | $1.2M | $11.1M | $1.8M | $2.0M | ||
| Depreciation & Amortization | $1.0M | $8.6M | $1.2M | $11.1M | $1.8M | $2.0M | ||
| Amortization | -- | $24.6M | -- | $114.0K | -- | -- | ||
| Other Operating Expenses | $-446.0K | $-103.0K | $-616.0K | $-59.0K | $-812.0K | $-838.0K | ||
| OPERATING INCOME | ||||||||
| Operating income | $-50.5M | $-25.3M | $-63.6M | $-93.4M | $-76.2M | $-81.5M | ||
| EBITDA | $-47.3M | $-18.7M | $-60.2M | $-83.2M | $-62.0M | $-69.2M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | $1.6M | -- | $3.8M | -- | -- | ||
| Intinc | $329.0K | $35.0K | $5.8M | $9.0K | $12.6M | $10.8M | ||
| Net Non-Operating Interest Income/Expense | $329.0K | $-1.5M | $5.8M | $-3.8M | $12.6M | $10.8M | ||
| Other Income/Expense | $146.0K | $1.4M | $-122.0K | $982.0K | $73.0K | $84.0K | ||
| Other Special Charges | $-146.0K | $-1.4M | $-122.0K | $-982.0K | $-73.0K | $-84.0K | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | -- | -- | -- | $2.5M | -- | -- | ||
| Special Income Charges | -- | -- | -- | $-29.5M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $27.0M | -- | -- | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-50.3M | $-27.3M | $-63.6M | $-94.3M | $-67.7M | $-75.6M | ||
| Pre-Tax Income | $-50.3M | $-28.2M | $-57.9M | $-98.1M | $-63.7M | $-70.8M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-3.0M | $-6.0M | $-3.1M | $9.4M | $-4.0M | $-4.8M | ||
| NET INCOME | ||||||||
| Net Income | $-50.3M | $-22.4M | $-57.9M | $-105.4M | $-63.7M | $-70.8M | ||
| Net Income (Continuing Operations) | $-50.3M | $-22.4M | $-57.9M | $-105.4M | $-63.7M | $-70.8M | ||
| Net Income (Discontinued Operations) | $-50.3M | $-22.4M | $-57.9M | $-105.4M | $-63.7M | $-70.8M | ||
| Net Income (Common Stockholders) | $-50.3M | $-22.4M | $-57.9M | $-105.4M | $-63.7M | $-70.8M | ||
| Normalized Income | $-53.4M | $-34.3M | -- | -- | -- | $-75.6M | ||
| TOTALS | ||||||||
| Total Expenses | $50.5M | $614.9M | $63.6M | $380.1M | $76.2M | $81.5M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $84.5M | $31.0M | $124.6M | $31.6M | $124.9M | $125.4M | ||
| Average Shares Outstanding (Diluted) | $84.5M | $31.0M | $124.6M | $31.6M | $124.9M | $125.4M | ||
| Shares Outstanding | $124.4M | $31.5M | $124.9M | $32.0M | $125.1M | $126.1M | ||
| Basic EPS | $-0.60 | $-0.72 | $-0.46 | $-3.34 | $-0.51 | $-0.56 | ||
| Basic EPS (Continuing Operations) | $-0.60 | $-0.72 | $-0.46 | $-3.4 | $-0.51 | $-0.56 | ||
| Diluted EPS | $-0.60 | $-0.72 | $-0.46 | $-3.34 | $-0.51 | $-0.56 | ||
| Diluted EPS (Continuing Operations) | $-0.60 | $-0.72 | $-0.46 | $-3.4 | $-0.51 | $-0.56 | ||
| OTHER METRICS | ||||||||
| Basic Discontinuous Operations | -- | -- | -- | $0.06 | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | $0.06 | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | $-29.0K | -- | $2.1M | -- | -- | ||
| Interest Expense Operating | -- | $-655.0K | -- | -- | -- | -- | ||
| Marketing Expense | -- | $61.5M | -- | $23.2M | -- | -- | ||
| Net Income Discontinuous Operations | -- | $-227.0K | -- | $2.1M | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | $-198.0K | -- | $-47.0K | -- | -- | ||
| Other Gand A | $21.1M | $51.8M | $25.9M | $42.5M | $28.9M | $31.0M | ||
| Restruct | -- | -- | -- | $2.5M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAUT | $0.68 | -1.0% | 153.40K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Nautilus Biotechnology Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW